# BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

> **NCT02569476** · PHASE1 · COMPLETED · sponsor: **BeiGene** · enrollment: 119 (actual)

## Conditions studied

- B-cell Lymphoid Malignancies

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT02569476
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-13
- **Primary completion:** 2020-09-02
- **Final completion:** 2020-09-02
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02569476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02569476, "BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02569476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*